Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-26-Q-9102Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/b93bd479d1e543169eef990a974044d3/view
Timeline
    Description

    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.

    Point(s) of Contact
    Stephanie Erpelding
    stephanie.j.erpelding.civ@health.mil
    Tracy Banks
    tracy.e.banks2.civ@health.mil
    Files
    Title
    Posted
    DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    The DoD Final Rule, effective August 26, 2015, clarifies the process for formulary placement of FDA-approved innovator drugs within the TRICARE Pharmacy Benefits Program. The Pharmacy and Therapeutics (P&T) Committee has up to 120 days to recommend tier placement for new molecular entities, new active ingredients, new dosage forms, and new combinations. Innovator drugs approved on or after the effective date will have a pending status and be treated as non-formulary. The P&T Committee evaluates these drugs based on clinical and cost-effectiveness data, with the DHA Director providing final approval. Manufacturers can submit price concessions during three solicitation windows. Innovator drugs are generally designated as Tier 3, requiring medical necessity for broader access or lower copays, and the DoD will not accept clinical presentations due to volume.
    Price Appendix FAQ NAD.pdf
    This government file outlines instructions for completing price appendix spreadsheets for federal government RFPs, specifically for BPA, ADP (non-FAMP Discount), and ADP (WAC Discount) categories. The document emphasizes reading formulary notes and filling in only yellow cells, with other cells being locked or auto-calculated. Key instructions include entering package size for BPA, non-FAMP prices for ADP (non-FAMP Discount), and WAC prices for ADP (WAC Discount). The file details how to indicate non-submission for a quote and provides calculations for price per unit and total calculated refund. It specifies that tables are provided for 10 NDCs, with options to request more if needed. Contacting POCs on the RFQ document is advised for questions or to submit more than 10 NDCs.
    Price List - Jascayd - Pulmonary-1- Idiopathic PF.xlsx
    The Department of Defense (DOD) Uniform Formulary Class for PULMONARY-1 AGENTS, specifically for IDIOPATHIC PULMONARY FIBROSIS, outlines requirements for Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs). Quotes for these agents are due by December 9, 2025, in advance of the P&T Committee Meeting on February 4-5, 2026. Manufacturers are instructed to submit fully executed signature pages along with quote information. The documents detail scenarios for Uniform Formulary and Non-Formulary drugs under BPAs, and Tier 2 and Tier 3 drugs under ADPs for TRICARE Retail Refund. The P&T Committee will review these agents according to 32 CFR 199.21(g)(5) and may apply Prior Authorization (PA), consider tier designations for agents without existing brands, and identify candidates for special reimbursement methods or complete exclusion from the TRICARE pharmacy benefit program. Agents for which an RFQ is not submitted or selected may be designated non-step preferred.
    Price List - Lynkuet - Gynecological Agents Misc- NA.xlsx
    The document outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Program for "GYNECOLOGICAL AGENTS MISCELLANEOUS," with a P&T Committee Meeting scheduled for February 4-5, 2026, and quotes due by December 9, 2025. It details the process for newly approved drugs, including "NO QUOTE" options for uniform and non-formulary scenarios in the Blanket Purchase Agreement Appendix. The Additional Discount Program Appendix includes TRICARE Retail Refund information for Tier 2 and Tier 3 drugs, with calculations based on non-FAMP and Federal Ceiling Price (FCP), and, for certain products, Wholesale Acquisition Cost (WAC) discounts. The P&T Committee will review these agents to determine formulary status, potential for prior authorization, special reimbursement methods, and possible exclusion from the TRICARE benefit. Manufacturers are reminded to submit fully executed signature pages with quote information.
    Price List - Palsonify - Endocrine Agents Misc - NA.xlsx
    The document outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Programs for "ENDOCRINE AGENTS MISCELLANEOUS" drugs, slated for review at the P&T Committee Meeting on February 4-5, 2026. Quotes for these programs are due by December 9, 2025. Manufacturers are invited to submit quotes for both formulary (Uniform and Non-Formulary) and retail refund scenarios (Tier 2 and Tier 3). The P&T Committee may consider prior authorization, special reimbursement methods, preferential status for non-generic agents (Tier 1), or complete exclusion from the TRICARE pharmacy benefit. Manufacturers must submit fully executed signature pages with their quotes, and agents without submitted or selected RFQs may be designated "non-step preferred (after-step)."
    Price List - Rhapsido - Atopy - NA.xlsx
    The Department of Defense (DOD) Uniform Formulary Class for ATOPY is soliciting quotes for newly approved drugs, with a P&T Committee Meeting scheduled for February 4-5, 2026, and quotes due by December 9, 2025. This request outlines requirements for both Blanket Purchase Agreements (BPAs) and an Additional Discount Program (ADP). Manufacturers are invited to submit quotes for both uniform and non-formulary drugs under the BPA, with specific NDC numbers provided. The ADP focuses on TRICARE retail refunds for Tier 2 and Tier 3 drugs, with calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) where applicable. Prior Authorization (PA) may apply, potentially including generic agents. The P&T Committee may recommend preferential status for non-generic agents or even exclude certain drugs from the TRICARE pharmacy benefit. Manufacturers must submit fully executed signature pages with their quotes, and a red highlight indicates an intent not to submit a quote.
    Price List - Tonmya - SMRs and Comb - TCA.xlsx
    The Department of Defense (DOD) Uniform Formulary is seeking quotes for Skeletal Muscle Relaxants and Combinations, specifically Tricyclic Antidepressants, to be reviewed at the P&T Committee Meeting on February 4-5, 2026. Quotes are due by December 9, 2025. This request outlines terms for Blanket Purchase Agreements and Additional Discount Programs. Manufacturers are required to submit fully executed signature pages along with quote information. The document specifies that agents will be reviewed for formulary status, potential preferential status (Tier 1), or complete exclusion from the TRICARE pharmacy benefit program. Prior Authorization may apply, and special reimbursement methods may be considered to encourage the use of high-value products. The price per unit for a given dosage form and strength must be consistent across all package sizes. The Wholesale Acquisition Cost (WAC) will be used for products without a Federal Ceiling Price (FCP), such as diabetic supplies, with the WAC discount remaining static throughout the agreement.
    Price List - Vyscoxa - Pain Agents - NSAID.xlsx
    The Department of Defense (DOD) Uniform Formulary is soliciting quotes for Pain Agents, specifically NSAIDs, for its P&T Committee Meeting on February 4-5, 2026. Quotes are due by December 9, 2025. The request includes two appendices: a Blanket Purchase Agreement for newly approved drugs and an Additional Discount Program Appendix. For both, manufacturers are asked to confirm their intent if not submitting a quote for specific NDC numbers under Uniform Formulary/Non-Formulary and Tier 2/Tier 3 categories, respectively. Notes emphasize the submission of fully executed signature pages with quotes. The formulary class may involve prior authorization and considerations for tier designation based on value and potential for special reimbursement. The P&T Committee may also recommend preferential status or complete exclusion from TRICARE pharmacy benefits. Pricing for the Blanket Purchase Agreement must be consistent across all package sizes within a given dispensing venue. For the Additional Discount Program, the TRICARE Retail Refund calculations are detailed, including Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts. Manufacturers are reminded that the quoted additional refund percentage remains static, but the calculated refund may change annually with non-FAMP updates, and WAC discounts apply to products without FCP.
    RFQ HT9402-26-Q-9102 NAD.pdf
    The Department of Defense (DOD) Defense Health Agency (DHA) has issued a Request for Quotation (RFQ) for pharmaceutical agents to be included on its Uniform Formulary (UF). This RFQ outlines the process for manufacturers to submit offers that reduce DOD costs for pharmaceutical agents, which will be considered by the DOD Pharmacy and Therapeutics (P&T) Committee. The committee evaluates the clinical and cost-effectiveness of drugs to classify them for cost-sharing purposes. Manufacturers can submit two types of quotes: UF Blanket Purchase Agreement (BPA) price quotes for Military Treatment Facilities (MTFs) and TRICARE Mail Order Pharmacy (TMOP), and UF Additional Discount Program (ADP) refund quotes for the TRICARE retail network. The RFQ details submission steps, general information, important dates, and evaluation criteria, emphasizing the consideration of both clinical effectiveness and cost in formulary decisions. It also includes appendices for submission checklists, BPA and ADP agreements, and NDC price lists.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program by evaluating the clinical and cost-effectiveness of various pharmaceutical agents, including oncological and antihemophilic agents, for inclusion in the DoD Uniform Formulary. Interested manufacturers must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Dimethyl Fumarate Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) is seeking offers for the procurement of Dimethyl Fumarate Capsules (120MG and 240MG delayed-release) through solicitation 36E79726R0003. This contract aims to establish a reliable supply source for these pharmaceutical products to support VA, Department of Defense (DoD), Indian Health Service (IHS), and Bureau of Prisons (BOP) facilities, with a contract structure that includes a one-year base ordering period and four one-year options. The products are critical for treating specific medical conditions, and offerors must comply with stringent requirements, including FDA regulations, Drug Supply Chain Security Act (DSCSA) compliance, and the provision of unique National Drug Codes (NDCs). The deadline for submitting offers has been extended to December 9, 2025, at 2:30 PM CST, and interested parties can contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov for further information.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Metaxalone Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in both 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal regulations and the submission of a subcontracting plan for large businesses. Metaxalone is a critical medication used for muscle relaxation, highlighting the importance of reliable supply for military personnel. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, at 3:00 PM EST, and can reach out to Jeremy Brown or Jason Wray for further inquiries.
    Tretinoin Cream
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Tretinoin Cream. The cream is used for various dermatological conditions and comes in different strengths (0.025%, 0.05%, and 0.1%) and tube sizes (20G and 45G). The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. It will establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. Interested parties should contact Ryan Ferry for more information. The projected solicitation date is February 2023.
    Ondansetron Orally Disintegrating Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    65--PYRIDOSTIGMINE BROM
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking quotes for the procurement of Pyridostigmine Bromide, specifically NSN 6505-01-725-2767, under a total small business set-aside. The requirement includes a quantity of 1,000 units to be delivered to the W05J Medical Maintenance Operations Division at Tobyhanna within 20 days after the order is placed. Pyridostigmine Bromide is a critical medication used to treat certain conditions, making this procurement essential for military medical operations. Interested vendors must submit their quotes electronically, and any inquiries should be directed to the buyer via email at DibbsBSM@dla.mil, as hard copies of the solicitation will not be provided.